World Kidney Day 2011: Protect your kidneys, save your heart

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 2, 2011, Pages 235-238

  Couser, William G ^a   Riella, Miguel C ^b   Martin, Sara ^b  

^a Joint International Society of Nephrology   (United States)

^b International Federation of Kidney Foundations ^*

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEATH; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY; KIDNEY DISEASE; MEDICAL SOCIETY; PROTEINURIA; RISK;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HEALTH PROMOTION; HUMANS; INTERNATIONAL AGENCIES; KIDNEY DISEASES; RISK ASSESSMENT; RISK FACTORS; SOCIETIES, MEDICAL; WORLD HEALTH;

EID: 79951882943     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.11031210     Document Type: Editorial

References (41)

1. World Health Organization: Preventing Chronic Diseases: A Vital Investment - WHO Global Report. 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases: Prevent and Control Cardiovascular Diseases, Cancers, Chronic Respiratory Diseases and Diabetes. Geneva, World Health Organization, 2005
2. Anderson GF, Chu E: Expanding priorities: Confronting chronic disease in countries with low income. N Engl J Med 356: 209-211, 2007 (Pubitemid 46143222)
3. Narayan KM, Ali MK, Koplan JP: Global noncommunicable diseases: Where worlds meet. N Engl J Med 363: 1196-1198, 2010
4. Ritz E, Bakris G, World Kidney Day Organising Committee: World Kidney Day: Hypertension and chronic kidney disease. Lancet 373: 1157-1158, 2009
5. Atkins RC, Zimmet P, ISN-IFKF World Kidney Day Steering Committee: Diabetic kidney disease: Act now or pay later. Nat Rev Nephrol 6: 134-136, 2010
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
7. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 17: 2034-2047, 2006 (Pubitemid 44036188)
8. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, Jong de PE, PREVEND study group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777-1782, 2002
9. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS: Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110: 32-35, 2004 (Pubitemid 38880131)
10. van Domburg RT, Hoeks SE, Welten GM, Chonchol M, Elhendy A, Poldermans D: Renal insufficiency and mortality in patients with known or suspected coronary artery disease. J Am Soc Nephrol 19: 158-163, 2008
11. Rashidi A, Sehgal AR, Rahman M, O'Connor AS: The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol 102: 1668-1673, 2008
12. McCullough PA, Li S, Jurkovitz CT, Stevens LA, Wang C, Collins AJ, Chen SC, Norris KC, McFarlane SI, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti JA, Whaley-Connell AT, Kidney Early Evaluation Program Investigators: CKD and cardiovascular disease in screened high-risk volunteer and general populations: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 51: S38-S45, 2008
13. McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, Chen SC, Li S, Singh A, Norris KC, Klag MJ, Bakris GL, KEEP Investigators: Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 167: 1122-1129, 2007 (Pubitemid 46919814)
14. McCullough PA, Li S, Jurkovitz CT, Stevens L, Collins AJ, Chen SC, Norris KC, McFarlane S, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti J, Whaley- Connell AT, Brenner RM, Bakris GL, KEEP Investigators: Chronic kidney disease: Prevalence of premature cardiovascular disease and relationship to short-term mortality. Am Heart J 156: 277-283, 2008
15. Astor BC, Hallan SI, Miller ER 3rd, Yeung E, Coresh J: Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 167: 1226-1233, 2008
16. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, Saito Y, Ota H, Nose T: The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 69: 1264-1271, 2006
17. van der Velde M, Halbesma N, de Charro FT, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT: Screening for albuminuria identifies individuals at increased renal risk. J Am Soc Nephrol 20: 852-862, 2009
18. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M, Cholesterol and Recurrent Events (CARE) Trial Investigators: Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: Analysis of a previously conducted randomised trial. BMJ 332: 1426, 2006
19. Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC, Coresh J: Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol 20: 2617-2624, 2009
20. Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Dobrzycki S: Prevalence of chronic kidney disease in elderly patients with normal serum creatinine levels undergoing percutaneous coronary interventions. Gerontology 56: 51-54, 2010
21. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, Wiebe N, Tonelli M, Alberta Kidney Disease Network: Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303: 423-429, 2010
22. Gansevoort RT, de Jong PE: The case for using albuminuria in staging chronic kidney disease. J Am Soc Nephrol 20: 465-468, 2009
23. Chronic Kidney Disease Prognosis Consortium: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 375, 2073-2081, 2010
24. Abdelhafiz AH, Brown SH, Bello A, El Nahas M: Chronic kidney disease in older people: Physiology, pathology or both? Nephron Clin Pract 116: 19-24, 2010
25. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
26. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354: 359-364, 1999 (Pubitemid 29355751)
27. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352: 1252-1256, 1998 (Pubitemid 28470337)
28. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
29. The ESCAPE trial group: Strict blood pressure control and progression of renal failure in children. N Engl J Med 361: 1639-1650, 2009
30. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH, Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators: Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110: 2809-2816, 2004
31. Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ, PREVEND IT Study Group: Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the Prevention of Renal and Vascular Endstage Disease (PREVEND) study and the Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT). Clin Ther 28: 432-444, 2006
32. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Brenner BM: Albuminuria: A therapeutic target for cardiovascular protection in type 2 diabetic nephropathy. Circulation 110: 921-927, 2004 (Pubitemid 39128617)
33. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D: Albuminuria is a target for renoprotective therapy independent from blood pressure in type II diabetic patients with nephropathy: Post hoc analysis from the Reduction in End Points in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 18: 1540-1546, 2007 (Pubitemid 46717521)
34. Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S, SMART (Supra Maximal Atacand Renal Trial) Investigators: Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 20: 893-900, 2009
35. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G: Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 19: 999-1007, 2008
36. Fried L: Are we ready to screen the general population for microalbuminuria? J Am Soc Nephrol 20: 686-688, 2009
37. El Nahas M: The global challenge of chronic kidney disease. Kidney Int 68: 2918-2929, 2005
38. Barsoum RS: Chronic Kidney disease in the developing world. N Engl J Med 354: 997-999, 2006
39. Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClellan W, Centers for Disease Control and Prevention Expert Panel: Comprehensive public health strategies for preventing the development, progression, and complications of CKD: Report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis 53: 522-535, 2009
40. James MT, Hemmelgarn BR, Tonelli M: Early recognition and prevention of CKD. Lancet 379: 1296-1309, 2010
41. Perico N, Bravo RF, De Leon FR, Remuzzi G: Screening for chronic kidney disease in emerging countries: feasibility and hurdles. Nephrol Dial Transplant 24: 1355-1358, 2009